Investing.com - Financial Markets Worldwide
👀 Ones to watch: Undervalued stocks to buy before they report Q3 earningsSee Undervalued Stocks

Abbott Laboratories (ABT)

NYSE
Symbol
Exchange
Currency
ABTNYSEUSD
0Q15LondonUSD
ABTBIVAMXN
ABTMexicoMXN
ABTSwitzerlandCHF
ABTXetraEUR
ABTFrankfurtEUR
ABTTradeGateEUR
ABTCLSantiagoCLP
ABTmBuenos AiresARS
ABTT34B3BRL
ABTViennaEUR
ABT_KZKASEUSD
ABTLimaUSD
Currency in USD
116.16
-0.54(-0.46%)
Real-time Data

ABT Comments

sell 112.13
super expent
All I got from Abbott’s Freestyle was a severe staphylococcus infection and wound up in the emergency room at Santa Barbara Cottage Hospital. All Abbott did was ignore me and my condition. They win the booby prize for customer care.
I am deeply troubled by the issues surrounding the Freestyle devices. After contracting a severe staphylococcus infection from the device, my concerns were exacerbated by Abbott's lack of prompt action for 8 months. Their customer support, located in the Philippines and Mexico City, presented challenges due to the absence of direct support in the US. This has led me to suspect a possible deliberate oversight on Abbott's part regarding staph infections caused by their devices. Moreover, online reports indicate that I am not alone in experiencing such infections. The culmination of these events resulted in a visit to the emergency room at a local hospital for urgent medical attention. Upon reaching out to CEO Robert Hunt with photographic evidence of the issue, I was disappointed to find that my concerns were not escalated to the head of customer service, Michael Taylor. Such negligence on the part of the CEO is unequivocally unacceptable and calls for immediate action. This situation demands swift and thorough investigation into the safety and efficacy of Abbott's Freestyle devices, as well as accountability for the handling of customer complaints at all levels of the organization.
what baby formula is all these companies being sued for?
ABT is a success story. There FreeStyle for diabetes is the best seller. The unit tells a diabetic person what foods cause the glucose spikes. The stock shot up because of their runaway successful Covid rapid tester. It has gone up by 20% this year and before we know it, it will be hitting $150.
Caspita sotto 100....
Buy 108.3
Abbott and WeightWatchers Partner to Support People Living with Diabetes in Attaining their Health Goals
super boom
super boom
Boom!!
its coiled like a snake it's ready to spring
best time to buy ABT!
Any idea what is the bottom?
106 but this is long term
Thank you.. Hope it will holds and does not drop below $100
excellent time to buy!!! good company and long run
It is time to buy! This is extra money, new business created by Covid. Icing on the cake.
buy now! i think?
what's the force behind this stock?
I don,t
They make Ensure and medical devices
 okie
Cổ phiếu sẽ giảm
It is only going up. Hate all you want but we are in for the gains. 🤷🏻‍♂️🤣
Best guess before the revenue report: 130$ and then continue going up after.
Earnings were Excellent and now the market is adjusting valuation! 🎉🥳 Any guesses since it already covered 2021 goal?
Me waiting for that rating change to $250 tomorrow 😣😣😣 Thank you Amen-Ra
I wish! Maybe in 5 years
I wasnt that far off lol $140 will do
25% dividend increase announced today for 2021. Still on the right track I would say. Still holding - on strong!
...
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.